% Expired Patents = 50.0

Forward Citations = 9

Loading Chart...

5 inventors (with patents filed for the assignee):

Thomas William Rademacher (6 out of 44 patents)

Manuel Martin-Lomas (4 out of 9 patents)

Irene Francois (4 out of 5 patents)

4. Hugo Norberto Caro (4 out of 9 patents)

5. Patricia McLean (2 out of 3 patents)

6 patents: Sort by Forward Citations

1. 7235533 - Compounds and their uses (2007-06-26),

2. 6953781 - Compounds and their uses (2005-10-11),

3. 6939857 - Compounds and their uses (2005-09-06),

4. 6716826 - Compounds and their uses (2004-04-06),

5. 6716592 - Materials and methods relating to the diagnosis and treatment of diabetes and obesity (2004-04-06),

6. 6495330 - Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes (2002-12-17),

Company Overview

Rodaris Pharmaceuticals Limited is a leading global pharmaceutical company that specializes in the research, development, and production of innovative medicines and healthcare products. With a focus on improving patient outcomes and quality of life, Rodaris Pharmaceuticals is dedicated to delivering high-quality, affordable medications to patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

6 Patents

#20 in Oxfordshire

#2,679 in United Kingdom

Oxfordshire, United Kingdom

Rodaris Pharmaceuticals Limited

Forward Citations = 9

5 inventors:

Thomas William Rademacher (6 out of 44 patents)

Manuel Martin-Lomas (4 out of 9 patents)

Irene Francois (4 out of 5 patents)

4. Hugo Norberto Caro (4 out of 9 patents)

5. Patricia McLean (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Rodaris Pharmaceuticals Limited. Retrieved from https://idiyas.com/company/rodaris-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]